18F-FET-PET显像在高级别胶质瘤和脑转移瘤中的应用:系统综述与Meta分析
本系统综述与Meta分析纳入26项研究共1206例患者/病灶,评估18F-FET-PET在高级别胶质瘤或脑转移瘤放疗计划、疗效反应评估及肿瘤复发与治疗相关改变鉴别中的诊断性能,结果显示其有一定前景,但需标准化图像解读方法的前瞻性研究进一步验证。
要点
- 胶质瘤放疗计划中,3项研究显示18F-FET摄取超出标准MRI钆增强20mm边界的合并比例为39%(95%CI 10-73%)。
- 鉴别胶质瘤复发与治疗相关改变,TBRmax 1.9-2.3的合并敏感度91%(95%CI 74-97%)、特异度84%(95%CI 69-93%)。
- 脑转移瘤鉴别中,TBRmax 2.15-3.11的合并敏感度和特异度均为82%(95%CI 74-88%)。
核心结论
- 18F-FET作为标准MRI的补充手段在原发性及转移性脑恶性肿瘤管理中显示前景,但需采用标准化图像解读方法在设计良好的前瞻性研究中进一步验证。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane系统综述数据库,纳入报告放疗计划、疗效反应评估及肿瘤复发与治疗相关改变鉴别中诊断试验参数的研究,排除影像组学研究。
- 共纳入26项研究,总计1206例患者/病灶。
- 采用QUADAS-2工具进行质量评价,并采用GRADE方法。
- 使用双变量随机效应模型生成敏感度和特异度的合并估计。
主要发现
- 胶质瘤放疗计划方面,3项研究中18F-FET摄取超出标准MRI钆增强20mm边界的患者合并比例为39%(95%CI,10-73%)。
- 3项研究显示18F-FET-PET可预测治疗早期反应者,而MRI未显示任何预后价值。
- 鉴别胶质瘤复发与治疗相关改变时,6项研究中TBRmax 1.9-2.3的合并敏感度为91%(95%CI,74-97%),合并特异度为84%(95%CI,69-93%)。
- 脑转移瘤方面,4项研究中TBRmax 2.15-3.11的合并敏感度为82%(95%CI,74-88%),合并特异度为82%(95%CI,74-88%)。
关键数值与推荐
- 胶质瘤复发与治疗相关改变鉴别:TBRmax 1.9-2.3,合并敏感度91%(95%CI,74-97%),合并特异度84%(95%CI,69-93%)。
- 脑转移瘤复发与治疗相关改变鉴别:TBRmax 2.15-3.11,合并敏感度82%(95%CI,74-88%),合并特异度82%(95%CI,74-88%)。
- 胶质瘤放疗计划:18F-FET摄取超出标准MRI钆增强20mm边界的合并比例39%(95%CI,10-73%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需采用标准化图像解读方法在设计良好的前瞻性研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide a summary of the diagnostic performance of 18F-FET-PET in the management of patients with high-grade brain gliomas or metastases from extracranial primary malignancies. METHODS: MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews databases were searched for studies that reported on diagnostic test parameters in radiotherapy planning, response assessment, and tumour recurrence/treatment-related changes differentiation. Radiomic studies were excluded. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool and the GRADE approach. A bivariate, random-effects model was used to produce summary estimates of sensitivity and specificity. RESULTS: Twenty-six studies with a total of 1206 patients/lesions were included in the analysis. For radiotherapy planning of glioma, the pooled proportion of patients from 3 studies with 18F-FET uptake extending beyond the 20 mm margin from the gadolinium enhancement on standard MRI was 39% (95% CI, 10-73%). In 3 studies, 18F-FET-PET was also shown to be predictive of early responders to treatment, whereas MRI failed to show any prognostic value. For the differentiation of glioma recurrence from treatment-related changes, the pooled sensitivity and specificity of TBRmax 1.9-2.3 from 6 studies were 91% (95% CI, 74-97%) and 84% (95% CI, 69-93%), respectively. The respective values for brain metastases from 4 studies were 82% (95% CI, 74-88%) and 82% (95% CI, 74-88%) using TBRmax 2.15-3.11. CONCLUSION: While 18F-FET shows promise as a complementary modality to standard-of-care MRI for the management of primary and metastatic brain malignancies, further validation with standardized image interpretation methods in well-designed prospective studies are warranted.
引用
- Singnurkar A, Poon R, Detsky J, et al. 18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. J Neurooncol. 2022. PMID: 36502457. doi:10.1007/s11060-022-04201-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。